- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00534274
Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy
Study of Positron Emission Tomography With 3'-Deoxy-3'-[18F] Fluoro-thymidine ([18F]-FLT) for the Evaluation of Response to Neoadjuvant Chemotherapy for Cancers of the Breast
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using 3'-deoxy-3'-(18F) fluorothymidine, may be effective in assessing the response to chemotherapy before surgery in treating locally advanced breast cancer.
PURPOSE: This clinical trial is studying how well positron emission tomography using 3'-deoxy-3'-(18F) fluorothymidine works in treating women with locally advanced cancer in one breast who are receiving chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Evaluate the efficacy of positron emission tomography (PET) utilizing 3'-deoxy-3'-(18F) fluorothymidine (^18F-FLT) to correctly identify response to neoadjuvant chemotherapy in women with locally advanced unilateral breast cancer.
- Correlate PET-^18F-FLT results with histological response.
Secondary
- Evaluate the correlation of early changes in tumor uptake of ^18F-FLT after the first course of chemotherapy with complete response after treatment completion.
- Evaluate the correlation of early changes in tumor uptake of ^18F-FLT with histologic response in biopsies obtained after 1 course of chemotherapy.
- Determine if the initial intensity of tumor uptake is a predictive value of response to chemotherapy.
- Determine if initial intensity of tumor uptake of ^18F-FLT varies according to histologic type of tumor, indices of proliferation, and tumor cellularity before therapy.
- Determine if the tumor uptake of ^18F-FLT during therapy varies according to histologic type of tumor, indices of proliferation, and tumor cellularity before therapy.
- Evaluate the role of TK1 on the kinetics of ^18 F-FLT.
- Analyze serum.
- Research biomarkers of genomics, transcription, and proteomics.
- Evaluate the toxicity of ^18F-FLT.
OUTLINE: This is a multicenter study.
Patients receive 3'-deoxy-3'-(18F) fluorothymidine (^18F-FLT) IV and undergo positron emission tomography (PET) before the first and second courses of neoadjuvant chemotherapy. Patients receiving bisequential chemotherapy undergo ^18F-FLT-PET before the change in drugs (usually the fourth or fifth course). All patients undergo a final ^18F-FLT-PET after the last chemotherapy course but before surgery.
After completion of study therapy, patients are followed for 1 month.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Angers, France, 49033
- Centre Hospitalier Regional et Universitaire d'Angers
-
Angers, France, 49036
- Centre Paul Papin
-
Bayonne, France, 64100
- Centre Hospitalier de la Cote Basque
-
Bordeaux, France, 33075
- Hopital Saint Andre
-
Bordeaux, France, 33076
- CHU de Bordeaux - Hôpital Pellegrin
-
Bordeaux, France, 33300
- Polyclinique Bordeaux Nord Aquitaine
-
Brest, France, 29609
- CHU Hopital A. Morvan
-
Caen, France, 14076
- Centre Regional Francois Baclesse
-
Clermont-Ferrand, France, 63011
- Centre Jean Perrin
-
Dijon, France, 21079
- Centre de Lutte Contre le Cancer Georges-Francois Leclerc
-
Lille, France, 59020
- Centre Oscar Lambret
-
Marseille, France, 13385
- CHU de la Timone
-
Marseille, France, 13273
- Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
-
Montpellier, France, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Nantes, France, 44093
- CHR Hotel Dieu
-
Nantes-Saint Herblain, France, 44805
- Centre Regional Rene Gauducheau
-
Nice, France, F-06202
- Hopital de l'Archet CHU de Nice
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Paris, France, 75970
- Hôpital Tenon
-
Paris, France, 75475
- Hôpital Saint-Louis
-
Poitiers, France, 86021
- CHU Poitiers
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Saint Cloud, France, 92211
- Centre René Huguenin
-
Tours, France, 37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically confirmed unilateral breast cancer
- T2 or T3, any N, M0
- Unifocal by mammography and ultrasound
- Negative for c-erbB2 by immunohistochemistry (IHC)
- Planning neoadjuvant chemotherapy comprising anthracyclines and/or taxanes, alone or combined
- Measurable disease by ultrasound
- Hormone receptor status not specified
Exclusion criteria:
- Bilateral disease
- Multifocal tumor
- Invasive grade I lobular cancer
- Metastatic disease
- Stage ≥ T4 disease
- Cutaneous invasion, major adherence, or inflammatory disease
- Tumor overexpressing c-erbB2 by IHC (HER 2+++)
- Suspected clinical or radiological lesion (examined or not)
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-1
- Female
- Menopausal status not specified
- Hematologic, hepatic, and renal function normal
- Not pregnant or nursing
- Fertile patients must use effective contraception
Exclusion criteria:
- Alcohol dependency or prior reaction to ethanol injection
- Impossible to receive study therapy due to geographical, social, or psychological reasons
- Prisoners or patients under supervision
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- See Disease Characteristics
Exclusion criteria:
- Participation in another concurrent therapeutic study with an experimental drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TEP FLT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Intensity of tumor uptake of 3'-deoxy-3'-(18F) fluorothymidine (18F-FLT) determined visually and correlated with histological or surgical response according to Sataloff criteria
Time Frame: Post surgery
|
Post surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Intensity of tumor uptake of 18F-FLT by standardized uptake value (SUV)
Time Frame: Post surgery
|
Post surgery
|
Variation of tumoral uptake as seen by positron emission tomography (PET) before, during, and after therapy as determined visually and by SUV
Time Frame: Post surgery
|
Post surgery
|
Intensity of the tumoral uptake of 18F-FLT on initial exam visually and by SUV
Time Frame: post surgery
|
post surgery
|
Histologic parameters: type, grade, mitotic index, CCIS , and microbiopsy embols after first course of chemotherapy (and on microbiopsy before therapeutic change of sequence in patients receiving bisequential chemotherapy)
Time Frame: post surgery
|
post surgery
|
Immunohistochemical evaluation (estrogen and progesterone receptors, c-erbB2, Ki-67, e-cadherin)
Time Frame: Post-surgery
|
Post-surgery
|
Rate of thymidine kinase 1 (TK1)
Time Frame: Post surgery
|
Post surgery
|
Toxicity by CTC-AE v. 3.0
Time Frame: Post surgery
|
Post surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Olivier Couturier, MD, Centre Hospitalier Regional et Universitaire d'Angers
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLT01 - UC-0140/0505
- FRE-FNCLCC-FLT-01/0505
- EU-20754
- 2005-005166-37 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on 3'-deoxy-3'-[18F]fluorothymidine
-
Frederick Daniel GrantDana-Farber Cancer InstituteCompleted
-
National Taiwan University HospitalUnknownBreast CancerTaiwan
-
Hamad Medical CorporationUnknownEssential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic StageQatar
-
UNC Lineberger Comprehensive Cancer CenterTerminatedGraft Vs Host DiseaseUnited States
-
Hamad Medical CorporationTerminatedPolycythemia Vera | Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic StageQatar
-
Dana-Farber Cancer InstituteCompletedCervical Cancer | Vaginal Cancer | Uterine Cancer | Carcinoma of the VulvaUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)SuspendedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
National Cancer Institute (NCI)WithdrawnCarcinoma, Non-Small-Cell Lung | Thymus Neoplasms
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedEsophageal CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedMelanomaUnited States